REGN1979 CD20 x CD3 Bispecific Antibody Treatment for Non-Hodgkin Lymphoma
by Dr. C.H. Weaver M.D. 12/2018
In a Phase 1 proof-of-concept trial, the experimentally REGN1979 bispecific antibody demonstrated a 100% overall and 80% complete response rate in 10 patients with relapsed or refractory follicular lymphoma. In addition, researchers reported an acceptable safety and tolerability profile with no observed dose-limiting toxicities at the 60th annual American Society of Hematology meeting.
REGN1979 is a bispecific monoclonal antibody designed to trigger the killing of cancer cells by binding to both CD3 on immune system T-cells and CD20 on B-cell lymphomas.
Israel Lowy, M.D., Ph.D., Head of Clinical and Translational Sciences, Oncology at Regeneron announced that. "Regeneron plans to initiate a potentially registrational Phase 2 clinical trial in 2019 investigating REGN1979 in relapsed or refractory follicular lymphoma. REGN1979 is also being investigated in combination with Libtayo® (cemiplimab-rwlc) in an ongoing Phase 1 study, which is the first clinical trial to combine a CD20xCD3 bispecific antibody with an immune checkpoint PD-1 or PD-L1 inhibitor."
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Regeneron…
TARRYTOWN, N.Y. , Dec. 1, 2018 /PRNewswire/ -- 100% overall and 80% complete response rate in 10 patients with relapsed or refractory follicular lymphoma treated with 5 mg or more of REGN1979 Plan to initiate in 2019 a potentially registrational Phase 2 trial in relapsed or refractory follicular